Form 6-K NOVARTIS AG For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Sandoz (NVS) Receives Positive EMA CHMP Opinion on Pregabalin as Epilepsy and GAD Treatment
April 24, 2015 7:53 AM EDTOn 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pregabalin Sandoz GmbH, intended for the treatment of epilepsy and generalized anxiety disorder. The applicant for this medicinal product is Sandoz GmbH, a unit of Novartis (NYSE:... More
Novartis (NVS) Tops Q1 EPS Views
April 23, 2015 9:22 AM EDTNovartis (NYSE: NVS) reported Q1 EPS of $1.33, $0.23 better than the analyst estimate of $1.10. Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $12.9 billion.
For total Group, Q1 divestments resulted in exceptional operating income gains totaling USD 12.8... More